Search research articles
Contact Us
Filters
Showing results (11-20 of 44) with videos related to
Page
of 5
Sort By:
Cell Death and Differentiation
|
March 19, 2005
Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication
J Milia, F Teyssier, F Dalenc, et al.
British Journal of Cancer
|
March 4, 2010
Participants' uptake of clinical trial results: a randomised experiment
J Mancini, D Genre, F Dalenc, et al.
ESMO Open
|
September 4, 2024
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?
C Valenza, D Trapani, F-C Bidard, et al.
British Journal of Cancer
|
January 14, 2012
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
E Brain, N Isambert, F Dalenc, et al.
Cancer Medicine
|
July 6, 2023
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings
D Hequet, N Hajjaji, E Charafe-Jauffret, et al.
European Journal of Cancer Care
|
August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study
F Dalenc, V Ribet, A B Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
L Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2011
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study
L Biganzoli, E Di Vincenzo, Z Jiang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
J-Y Pierga, F-C Bidard, C Cropet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2012
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
M Arnedos, V Scott, B Job, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 44) with videos related to
Sort By:
Page
of 5
Cell Death and Differentiation
|
March 19, 2005
Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication
J Milia, F Teyssier, F Dalenc, et al.
British Journal of Cancer
|
March 4, 2010
Participants' uptake of clinical trial results: a randomised experiment
J Mancini, D Genre, F Dalenc, et al.
ESMO Open
|
September 4, 2024
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?
C Valenza, D Trapani, F-C Bidard, et al.
British Journal of Cancer
|
January 14, 2012
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
E Brain, N Isambert, F Dalenc, et al.
Cancer Medicine
|
July 6, 2023
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings
D Hequet, N Hajjaji, E Charafe-Jauffret, et al.
European Journal of Cancer Care
|
August 24, 2017
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study
F Dalenc, V Ribet, A B Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
L Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2011
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study
L Biganzoli, E Di Vincenzo, Z Jiang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
J-Y Pierga, F-C Bidard, C Cropet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2012
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
M Arnedos, V Scott, B Job, et al.
Page
of 5